| Trial ID: | L4870 |
| Source ID: | NCT00562250
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Glimepiride|DRUG: Dapagliflozin + Glimepiride
|
| Outcome Measures: |
Primary: Maximum plasma concentration and exposure to glimepiride and dapagliflozin when administered alone and administered together, plasma concentrations will be measures as specified timepoints for 72 hours after each administred dose | Secondary: Measures of the plasma concentration of the active metabolite of glimepiride when administered alone or coadministered with glimepiride, for 72 hours after each administered dose|Recorded adverse events, for 72 hours after each administered dose
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Bristol-Myers Squibb
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
11
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-05
|
| Completion Date: |
2008-08
|
| Results First Posted: |
|
| Last Update Posted: |
2016-10-17
|
| Locations: |
Local Institution, Vicente Lopez, Buenos Aires, 1602, Argentina
|
| URL: |
https://clinicaltrials.gov/show/NCT00562250
|
